Natural approaches to prevention and treatment of infections of the lower urinary tract

Alternative Medicine Review

Volumn 13, Issue 3, 2008, Pages 227-244

  Head, Kathleen A ^a  

^a Thorne Research Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; BERBERINE; COTRIMOXAZOLE; CRANBERRY EXTRACT; CYCLOPHOSPHAMIDE; ESTRIOL; FERROUS SULFATE; FOLIC ACID; MANNOSE; MIDAZOLAM; NORFLOXACIN; POTASSIUM SALT; PROBIOTIC AGENT; RETINOL; TIZANIDINE; VACCINIUM MYRTILLUS EXTRACT; WARFARIN;

AGRIMONIA; ALKALINIZATION; ARCTIUM; ARCTOSTAPHYLOS UVA URSI; CELERY; CLINICAL TRIAL; CRANBERRY; CYSTITIS; DANDELION; DIABETES MELLITUS; DRUG CONTRAINDICATION; DRUG SAFETY; DYSURIA; ELM; ELYMUS; HEMORRHAGIC CYSTITIS; HUMAN; HYDRANGEA; INFECTION PREVENTION; JUNIPERUS; LINGONBERRY; MAIZE; MEDICINAL PLANT; MENTHA PIPERITA; NEUROGENIC BLADDER; NONHUMAN; PATHOGENESIS; POSTMENOPAUSE; PREGNANCY; REVIEW; RISK FACTOR; SYMPTOMATOLOGY; URINARY TRACT INFECTION;

ANIMALS; BEVERAGES; FEMALE; HUMANS; MALE; PHYTOTHERAPY; PLANT EXTRACTS; PREGNANCY; PROBIOTICS; URETHRAL DISEASES; URINARY BLADDER DISEASES; URINARY TRACT INFECTIONS;

EID: 53549124994     PISSN: 10895159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (98)

1. http://kidney.niddk.nih.gov/kudiseases/pubs/utiadult/ [Accessed June 4, 2008]
2. Kasper DL, Fauci AS, Longo DL, et al. Harrison's Principles of Internal Medicine. 16th ed. New York, NY: McGraw Hill; 2005.
3. Remis RS, Gurwith MJ, Gurwith D, et al. Risk factors for urinary tract infection. Am J Epidemiol 1987;126:685-694.
4. Foxman B, Chi JW. Health behavior and urinary tract infection in college-aged women. J Clin Epidemiol 1990;43:329-337.
5. Hooton TM, Scholes D, Hughes JP, et al. A prospective study of risk factors for symptomatic urinary tract infection in young women. N Engl J Med 1996;335:468-474.
6. Hooton TM, Scholes D, Stapleton AE, et al. A prospective study of asymptomatic bacteriuria in sexually active young women. N Engl J Med 2000;343:992-997.
7. Foxman B, Geiger AM, Palin K, et al. First-time urinary tract infection and sexual behavior. Epidemiology 1995;6:162-168.
8. Delzell JE Jr, Lefevre ML. Urinary tract infections during pregnancy. Am Fam Physician 2000;61:713-721.
9. Le J, Briggs GG, McKeown A, Bustillo G. Urinary tract infections during pregnancy. Ann Pharmacother 2004;38:1692-1701.
10. Sharami SH, Afrakhteh M, Shakiba M. Urinary tract infections in pregnant women with bacterial vaginosis. J Obstet Gynaecol 2007;27:252-254.
11. Harmanli OH, Cheng GY, Nyirjesy P, et al. Urinary tract infections in women with bacterial vaginosis. Obstet Gynecol 2000;95:710-712.
12. Conde-Agudelo A, Villar J, Lindheimer M. Maternal infection and risk of preeclampsia: systematic review and metaanalysis. Am J Obstet Gynecol 2008;198:7-22.
13. Herraiz MA, Hernandez A, Asenjo E, Herraiz I. Urinary tract infection in pregnancy. Enferm Infecc Microbiol Clin 2005;23:40-46. [Article in Spanish]
14. Jackson SL, Boyko EJ, Scholes D, et al. Predictors of urinary tract infection after menopause: a prospective study. Am J Med 2004;117:903-911.
15. Boyko EJ, Fihn SD, Scholes D, et al. Diabetes and the risk of acute urinary tract infection among postmenopausal women. Diabetes Care 2002;25:1778-1783.
16. Boyko EJ, Fihn SD, Scholes D, et al. Risk of urinary tract infection and asymptomatic bacteriuria among diabetic and nondiabetic postmenopausal women. Am J Epidemiol 2005;161:557-564.
17. Brown JS, Vittinghoff E, Kanaya AM, et al. Urinary tract infections in postmenopausal women: effect of hormone therapy and risk factors. Obstet Gynecol 2001;98:1045-1052.
18. Wellens A, Garofalo C, Nguyen H, et al. Intervening with urinary tract infections using anti-adhesives based on the crystal structure of the FimH-oligomannose-3 complex. PLoS ONE 2008;3:e2040.
19. Stothers L. A randomized trial to evaluate effectiveness and cost effectiveness of naturopathic cranberry products as prophylaxis against urinary tract infection in women. Can J Urol 2002;9:1558-1562.
20. Haverkorn MJ, Mandigers J. Reduction in bacteriuria and pyuria using cranberry juice. JAMA 1994;272:590.
21. Avorn J, Monane M, Gurwitz JH, et al. Reduction of bacteriuria and pyuria after ingestion of cranberry juice. JAMA 1994;271:751-754.
22. McMurdo ME, Bissett LY, Price RJ, et al. Does ingestion of cranberry juice reduce symptomatic urinary tract infections in older people in hospital? A double-blind, placebo-controlled trial. Age Ageing 2005;34:256-261.
23. Reid G, Hsiehl J, Potter P, et al. Cranberry juice consumption may reduce biofilms on uroepithelial cells: pilot study in spinal cord injured patient. Spinal Cord 2001;39:26-30.
24. Linsenmeyer TA, Harrison B, Oakley A, et al. Evaluation of cranberry supplement for reduction of urinary tract infections in individuals with neurogenic bladders secondary to spinal cord injury. A prospective, double-blinded, placebo-controlled, crossover study. J Spinal Cord Med 2004;27:29-34.
25. Schlager TA, Anderson S, Trudell J, Hendley JO. Effect of cranberry juice on bacteriuria in children with neurogenic bladder receiving intermittent catheterization. J Pediatr 1999;135:698-702.
26. Foda MM, Middlebrook PF, Gatfield CT, et al. Efficacy of cranberry in prevention of urinary tract infection in a susceptible pediatric population. Can J Urol 1995;2:98-102.
27. Jepson RG, Craig JC. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev 2008;1:CD001321.
28. Kontiokari T, Sundqvist K, Nuutinen M, et al. Randomised trial of cranberry-lingonberry juice and Lactobacillus GG drink for the prevention of urinary tract infections in women. BMJ 2001;322:1571.
29. Howell AB. Bioactive compounds in cranberries and their role in prevention of urinary tract infections. Mol Nutr Food Res 2007;51:732-737.
30. Schultz A. Efficacy of cranberry juice and ascorbic acid in acidifying the urine in multiple sclerosis subjects. J Community Health Nurs 1984;1:159-169.
31. Sobota AE. Inhibition of bacterial adherence by cranberry juice: potential use for the treatment of urinary tract infections. J Urol 1984;431:1013-1016.
32. Di Martino P, Agniel R, David K, et al. Reduction of Escherichia coli adherence to uroepithelial bladder cells after consumption of cranberry juice: a double-blind randomized placebo-controlled cross-over trial. World J Urol 2006;24:21-27.
33. Greenberg JA, Newmann SJ, Howell AB. Consumption of sweetened dried cranberries versus unsweetened raisins for inhibition of uropathogenic Escherichia coli adhesion in human urine: a pilot study. J Altern Complement Med 2005;41:875-878.
34. Howell AB, Reed JD, Krueger CG, et al. A-type cranberry proanthocyanidins and uropathogenic bacterial anti-adhesion activity. Phytochemistry 2005;66:2281-2291.
35. Dugoua JJ, Seely D, Perri D, et al. Safety and efficacy of cranberry (Vaccinium macrocarpon) during pregnancy and lactation. Can J Clin Pharmacol 2008;15:e80-e86.
36. Terris MK, Issa MM, Tacker JR. Dietary supplementation with cranberry concentrate tablets may increase the risk of nephrolithiasis. Urology 2001;57:26-29.
37. Paeng CH, Sprague M, Jackevicius CA. Interaction between warfarin and cranberry juice. Clin Ther 2007;29:1730-1735.
38. Mohammed Abdul MI, Jiang X, Williams KM, et al. Pharmacodynamic interaction of warfarin with cranberry but not with garlic in healthy subjects. Br J Pharmacol 2008 Jun 2. [Epub ahead of print]
39. Li Z, Seeram NP, Carpenter CL, et al. Cranberry does not affect prothrombin time in male subjects on warfarin. J Am Diet Assoc 2006;406:2057-2061.
40. Lilja JJ, Backman JT, Neuvonen PJ. Effects of daily ingestion of cranberry juice on the pharmacokinetics of warfarin, tizanidine, and midazolam - probes of CYP2C9, CYP1A2, and CYP3A4. Clin Pharmacol Ther 2007;81:833-839.
41. Greenblatt DJ, von Moltke LL, Perloff ES, et al. Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: in vitro and clinical studies. Clin Pharmacol Ther 2006;79:125-133.
42. Ofek I, Goldhar J, Zafriri D, et al. Anti-Escherichia coli adhesin activity of cranberry and blueberry juices. N Engl J Med 1991;324:1599.
43. Ofek I, Goldhar J, Sharon N. Anti-Escherichia coli adhesin activity of cranberry and blueberry juices. Adv Exp Med Biol 1996;408:179-183.
44. Weiss EL, Lev-Dor R, Sharon N, Ofek I. Inhibitory effect of a high-molecular-weight constituent of cranberry on adhesion of oral bacteria. Crit Rev Food Sci Nutr 2002;42:285-292.
45. Cernakova M, Kostalova D, Antimicrobial activity of berberine - a constituent of Mahonia aquifolium. Folia Microbiol (Praha) 2002;47:375-378.
46. Scazzocchio F, Cometa MF, Tomassini L, Palmery M, Antibacterial activity of Hydrastis canadensis extract and its major isolated alkaloids. Planta Med 2001;67:561-564.
47. Yan D, Jin C, Xiao XH, Dong XP. Antimicrobial properties of berberines alkaloids in Coptis chinensis Franch by microcalorimetry. J Biochem Biophys Methods 2008;70:845-849.
48. Domadia PN, Bhunia A, Sivaraman J, et al, Berberine targets assembly of Escherichia coli cell division protein FtsZ. Biochemistry 2008;47:3225-3234.
49. Sun D, Abraham SN, Beachey EH. Influence of berberine sulfate on synthesis and expression of Pap fimbrial adhesin in uropathogenic Escherichia coli. Antimicrob Agents Chemother 1988;32:1274-1277.
50. Sun D, Courtney HS, Beachey EH. Berberine sulfate blocks adherence of Streptococcus pyogenes to epithelial cells, fibronectin, and hexadecane. Antimicrob Agents Chemother 1988;32:1370-1374.
51. Xu X, Malave A. Protective effect of berberine on cyclophosphamide- induced haemorrhagic cystitis in rats. Pharmacol Toxicol 2001;88:232-237.
52. Rabbani GH, Butler T, Knight J, et al. Randomized controlled trial of berberine sulfate therapy for diarrhea due to enterotoxigenic Escherichia coli and Vibrio cholerae. J Infect Dis 1987;155:979-984.
53. Sack RB, Froehlich JL. Berberine inhibits intestinal secretory response of Vibrio cholerae and Escherichia coli enterotoxins. Infect Immun 1982;35:471-475.
54. Zhu B, Ahrens FA. Effect of berberine on intestinal secretion mediated by Escherichia coli heat-stable enterotoxin in jejunum of pigs. Am J Vet Res 1982;43:1594-1598.
55. Uva ursi. In: LaGow B, chief editor. PDR for Herbal Medicines, 3rd ed. Montvale, NJ: Thomson; 2004:847-851.
56. Yarnell E. Botanical medicine for cystitis. Altern Complement Ther 1997;3:269-275.
57. Schindler G, Patzak U, Brinkhaus B, et al. Urinary excretion and metabolism of arbutin after oral administration of Arctostaphylos uvae ursi extract as film-coated tablets and aqueous solution in healthy humans. J Clin Pharmacol 2002;42:920-927.
58. Frohne D. The urinary disinfectant effect of extract from leaves uva ursi. Planta Med 1970;18:1-25. [Article in German]
59. Kedzia B, Wrocinski T, Mrugasiewicz K, et al. Antibacterial action of urine containing products of arbutin metabolism. Med Dosw Mikrobiol 1975;27:305-314. [Article in Polish]
60. Bratman S, Kroll D. Uva ursi (bearberry). In: Clinical Evaluation of Medicinal Herbs and Other Therapeutic Natural Products. Rocklin, CA: Prima Publishing; 1999.
61. Werbach M, Murray MT. Urinary tract infection. In: Botanical Influences on Illness. 2nd ed. Tarzana, CA: Third Line Press, Inc; 2000:567-569.
62. Turi M, Turi E, Kotjalg S, Mikelsaar M. Influence of aqueous extracts of medicinal plants on surface hydrophobicity of Escherichia coli strains of different origin. APMIS 1997;405:956-962.
63. Beaux D, Fleurentin J, Mortier F. Effect of extracts of Orthosiphon stamineus Benth, Hieracium pilosella L., Sambucus nigra L. and Arctostaphylos uva-ursi (L.) Spreng. in rats. Phytother Res 1999;43:222-225.
64. Kubo M, Ito M, Nakata H, Matsuda H. Pharmacological studies on leaf of Arctostaphylos uva-ursi (L.) Spreng. I. Combines effect of 50% methanolic extract from Arctostaphylos uva-ursi (L.) Spreng, (bearberry leaf) and prednisolone on immuno-inflammation. Yakugaku Zasshi 1990;410:59-67. [Article in Japanese]
65. Larsson B, Jonasson A, Fianu S. Prophylactic effect of UVA-E in women with recurrent cystitis: a preliminary report. Curr Ther Res 1993;53:441-443.
66. Simpson D, Buchu - South Africa's amazing herbal remedy. Scott Med J 1998;43:189-191.
67. Mills S, Bone K. Buchu. In: Principles and Practice of Phytotherapy: Modern Herbal Medicine. Churchill Livingstone; 2000:310-312.
68. Barnes J, Anderson LA, Phillipson JD. Herbal Medicines. 3rd ed. Grayslake, IL: Pharmaceutical Press; 2007.
69. Pereira RS, Sumita TC, Furlan MR, et al. Antibacterial activity of essential oils on microorganisms isolated from urinary tract infection. Rev Saude Publica 2004;38:326-328. [Article in Portuguese]
70. Koch E. Extracts from fruits of saw palmetto (Sabal serrulata) and roots of stinging nettle (Urtica dioica): viable alternatives in the medical treatment of benign prostatic hyperplasia and associated lower urinary tracts symptoms. Planta Med 2001;67:489-500.
71. Ulbricht CE, Basch EM. Natural Standards: Herb & Supplement Reference. St. Louis, MO: Elsevier/Mosby; 2005.
72. Ochoa-Brust GJ, Fernandez AR, Villanueva-Ruiz GJ, et al. Daily intake of 100 mg ascorbic acid as urinary tract infection prophylactic agent during pregnancy. Acta Obstet Gynecol Stand 2007;86:783-787.
73. Yilmaz A, Bahat E, Yilmaz GG, et al. Adjuvant effect of vitamin A on recurrent lower urinary tract infections. Pediatr Int 2007;49:310-313.
74. Spooner JB. Alkalinisation in the management of cystitis. J Int Med Res 1984;12:30-34.
75. Strassner C, Friesen A. Therapy of candiduria by alkalinization of the urine. Oral treatment with potassium-sodium-hydrogen citrate. Fortschr Med 19954;13:359-362. [Article in German]
76. Ofek I, Beachey EH. Mannose binding and epithelial cell adherence of Escherichia coli. Infect Immun 1978;22:247-254.
77. Hung CS, Bouckaert J, Hung D, et al. Structural basis of tropism of Escherichia coli to the bladder during urinary tract infection. Mol Microbiol 2002;44:903-915.
78. Firon N, Ashkenazi S, Mirelman D, et al. Aromatic alpha-glycosides of mannose are powerful inhibitors of the adherence of typel fimbriated Escherichia coli to yeast and intestinal epithelial cells. Infect Immun 1987;55:472-476.
79. Schaeffer AJ, Chmiel JS, Duncan JL, Falkowski WS. Mannose-sensitive adherence of Escherichia coli to epithelial cells from women with recurrent urinary tract infections. J Urol 1984;131:906-910.
80. Schaeffer AJ, Amundsen SK, Jones JM. Effect of carbohydrates on adherence of Escherichia coli to human urinary tract epithelial cells. Infect Immun 1980;30:531-537.
81. Kontiokari T, Laitinen J, Jarvi L, et al. Dietary factors protecting women from urinary tract infection. Am J Clin Nutr 2003;77:600-604.
82. Manges AR, Smith SP, Lau BJ, et al. Retail meat consumption and the acquisition of antimicrobial resistant Escherichia coli causing urinary tract infections: a case-control study. Foodborne Pathog Dis 2007;4:419-431.
83. Osset J, Bartolome RM, Garcia E, Andreu A. Assessment of the capacity of Lactobacillus to inhibit the growth of uropathogens and block their adhesion to vaginal epithelial cells. J Infect Dis 2001;183:485-491.
84. Kwok L, Stapleton AE, Stamm WE, et al. Adherence of Lactobacillus crispatus to vaginal epithelial cells from women with or without a history of recurrent urinary tract infection. J Urol 2006;176:2050-2054.
85. Hutt P, Shchepetova J, Loivukene K, et al. Antagonistic activity of probiotic Lactobacilli and Bifidobacteria against entero- and uropathogens. J Appl Microbiol 2006;100:1324-1332.
86. Patton DL, Cosgrove Sweeney YT, Antonio MA, et al. Lactobacillus crispatus capsules: single-use safety study in the Macaca nemestrina model. Sex Transm Dis 2003;30:568-570.
87. Fraga M, Scavone P, Zunino P. Preventive and therapeutic administration of an indigenous Lactobacillus sp. strain against Proteus mirabilis ascending urinary tract infection in a mouse model. Antonie Van Leeuwenhoek 2005;88:25-34.
88. Uehara S, Monden K, Nomoto K, et al. A pilot study evaluating the safety and effectiveness of Lactobacillus vaginal suppositories in patients with recurrent urinary tract infection. Int J Antimicrob Agents 2006;28:S30-S34.
89. Reid G, Bruce AW, Taylor M. Influence of three-day antimicrobial therapy and Lactobacillus vaginal suppositories on recurrence of urinary tract infections. Clin Ther 1992;14:11-16.
90. Reid G, Bruce AW, Taylor M. Instillation of Lactobacillus and stimulation of indigenous organisms to prevent recurrence of urinary tract infections. Microecol Ther 1995;23:32-45.
91. Cited in: Barrons R, Tassone D. Use of Lactobacillus probiotics for bacterial genitourinary infections in women: a review. Clin Ther 2008;30:453-468.
92. Baerheim A, Larsen E, Digranes A. Vaginal application of Lactobacilli in the prophylaxis of recurrent lower urinary tract infection in women. Scand J Prim Health Care 1994;12:239-243.
93. Czaja CA, Stapleton AE, Yarova-Yarovaya Y, Stamm WE. Phase I trial of a Lactobacillus crispatus vaginal suppository for prevention of recurrent urinary tract infection in women. Infect Dis Obstet Gynecol 2007;2007:35387.
94. Reid G, Bruce AW, Fraser N, et al. Oral probiotics can resolve urogenital infections. FEMS Immunol Med Microbiol 2001;30:49-52.
95. Dani C, Biadaioli R, Bertini G, et al. Probiotics feeding in prevention of urinary tract infection, bacterial sepsis and necrotizing enterocolitis in preterm infants. A prospective double-blind study. Biol Neonate 2002;82:103-108.
96. Gerasimov SV. Probiotic prophylaxis in pediatric recurrent urinary tract infections. Clin Pediatr (Phila) 2004;43:95-98.
97. Akil I, Yilmaz O, Kurutepe S, et al. Influence of oral intake of Saccharomyces boulardii on Escherichia coli in enteric flora. Pediatr Nephrol 2006;21:807-810.
98. Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Eng J Med 1993;329:753-756.